Colestimide, a resin that binds and eliminates bile acids, seems to be an effective treatment for obesity and type 2 diabetes — according to a new report. "Since bile acid-binding resins have been clinically used as cholesterol-lowering agents," the researchers suggest, "it is reasonable to try this therapy in patients with type 2 diabetes and dyslipidemia," or abnormal levels of blood fats.
Colestimide is marketed as Cholebine in Japan by Mitsubishi Pharma Corporation.
Dr. Misato Kobayashi and Dr. Hiroshi Ikegami told Diabetes in Control that, "Since dyslipidemia in patients with type 2 diabetes leads to high mortality, this research provides a message on the beneficial effect of this kind of drug.
The researchers, from Osaka University Graduate School of Medicine, Suita, and from Kinki University School of Medicine, Osaka, Japan and their colleagues investigated the effects of colestimide on blood glucose levels in mice that develop a disease akin to type 2 diabetes.
Colestimide treatment prevented diet-induced obesity and high blood sugar, and ameliorated established diet-induced obesity in mice, the team discovered.
Levels of "bad" LDL cholesterol decreased significantly without affecting "good" HDL cholesterol levels, the results indicate.
While it might be tempting to try this therapy for type 2 diabetes without dyslipidemia, "it would be better to wait for results from controlled trials," the researchers advised.
Diabetes, January 2007
For the diabetic patient, it’s not the cholesterol that’s the problem. It’s the number of LDL particles, especially small LDL particles. To see the real risk, use the NMR LipoProfile(r) test, the only test that directly measures the number of LDL particles and the number of small LDL particles – the particles shown to be more predictive of CHD events than LDL-C. Click here to learn more.